Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARNANASDAQ:AVIRNASDAQ:CCXINASDAQ:GWPHNASDAQ:HCM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARNAArena Pharmaceuticals$99.99$97.65$45.50▼$100.00$6.17B0.551.56 million shs107 shsAVIRAtea Pharmaceuticals$3.75+3.0%$3.10$2.46▼$4.15$320.93M0.25323,353 shs139,942 shsCCXIChemoCentryx$51.99$51.95$14.95▼$52.00$3.71B1.221.68 million shs113 shsGWPHGW Pharmaceuticals$218.96$218.59$87.07▼$219.57$6.86B2.15899,771 shsN/AHCMHUTCHMED$15.88+3.0%$14.83$11.51▼$21.50$2.77B0.52100,495 shs11,386 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARNAArena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AVIRAtea Pharmaceuticals-0.82%+1.11%+14.47%+37.36%+12.00%CCXIChemoCentryx0.00%0.00%0.00%0.00%0.00%GWPHGW Pharmaceuticals0.00%0.00%0.00%0.00%0.00%HCMHUTCHMED-2.98%+2.46%+0.46%+30.57%-16.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARNAArena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAVIRAtea Pharmaceuticals2.3365 of 5 stars3.32.00.00.00.62.51.3CCXIChemoCentryxN/AN/AN/AN/AN/AN/AN/AN/AGWPHGW PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AHCMHUTCHMED1.3314 of 5 stars2.04.00.00.00.00.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARNAArena Pharmaceuticals 0.00N/AN/AN/AAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0060.00% UpsideCCXIChemoCentryx 0.00N/AN/AN/AGWPHGW Pharmaceuticals 0.00N/AN/AN/AHCMHUTCHMED 2.00Hold$19.0019.65% UpsideCurrent Analyst Ratings BreakdownLatest CCXI, AVIR, GWPH, ARNA, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARNAArena Pharmaceuticals$50K123,305.67N/AN/A$10.94 per share9.14AVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/ACCXIChemoCentryx$32.22M115.14N/AN/A$4.09 per share12.71GWPHGW Pharmaceuticals$311.33M22.05$0.01 per share18,588.22$23.48 per share9.33HCMHUTCHMED$630.20M4.39$0.29 per share55.04$4.43 per share3.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARNAArena Pharmaceuticals-$616.43M-$10.13N/AN/AN/AN/A-69.83%-62.35%N/AAVIRAtea Pharmaceuticals-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/6/2025 (Estimated)CCXIChemoCentryx-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/AGWPHGW Pharmaceuticals-$9.02M-$0.24N/A608.22N/A-11.05%-7.46%-6.13%N/AHCMHUTCHMED$37.73MN/A0.0010.88N/AN/AN/AN/AN/ALatest CCXI, AVIR, GWPH, ARNA, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARNAArena PharmaceuticalsN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ACCXIChemoCentryxN/AN/AN/AN/AN/AGWPHGW PharmaceuticalsN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARNAArena Pharmaceuticals0.058.598.59AVIRAtea PharmaceuticalsN/A19.9419.94CCXIChemoCentryx0.024.544.47GWPHGW Pharmaceuticals0.015.134.31HCMHUTCHMED0.082.832.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARNAArena Pharmaceuticals83.77%AVIRAtea Pharmaceuticals86.67%CCXIChemoCentryx81.09%GWPHGW Pharmaceuticals81.00%HCMHUTCHMED8.82%Insider OwnershipCompanyInsider OwnershipARNAArena Pharmaceuticals2.41%AVIRAtea Pharmaceuticals18.10%CCXIChemoCentryx8.30%GWPHGW Pharmaceuticals3.10%HCMHUTCHMED3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARNAArena Pharmaceuticals44861.66 million60.17 millionOptionableAVIRAtea Pharmaceuticals7085.58 million70.09 millionOptionableCCXIChemoCentryx17871.36 million65.43 millionOptionableGWPHGW Pharmaceuticals1,16131.35 millionN/AOptionableHCMHUTCHMED1,811174.32 million168.05 millionNot OptionableCCXI, AVIR, GWPH, ARNA, and HCM HeadlinesRecent News About These CompaniesHUTCHMED to Announce 2025 Half-Year Financial ResultsJuly 3, 2025 | globenewswire.comHUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor TherapyJune 30, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by Wall Street ZenJune 29, 2025 | americanbankingnews.comHUTCHMED (NASDAQ:HCM) Upgraded by Wall Street Zen to "Strong-Buy" RatingJune 27, 2025 | marketbeat.comHUTCHMED (China) Limited (HCM.L) - Yahoo FinanceJune 26, 2025 | nz.finance.yahoo.comHUTCHMED (China) Limited (HCM) - Yahoo FinanceJune 26, 2025 | au.finance.yahoo.comHow Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52% - NasdaqJune 25, 2025 | nasdaq.comHow Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52%June 23, 2025 | zacks.comPaycom Software: Automating Payroll And HCM Solutions; Initiate With 'Buy'June 22, 2025 | seekingalpha.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?June 17, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Downgraded to "Buy" Rating by Wall Street ZenJune 14, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?June 12, 2025 | marketbeat.comHutchmed introduces new share options and LTIP awardsJune 11, 2025 | uk.investing.comHUTCHMED Grants Share Options and LTIP Awards to Boost Talent RetentionJune 10, 2025 | tipranks.comWall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?June 5, 2025 | zacks.comChina accepts NDA for sintilimab and fruquintinib combo in kidney cancerJune 4, 2025 | msn.comInnovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell CarcinomaJune 4, 2025 | prnewswire.comHUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell CarcinomaJune 4, 2025 | globenewswire.comHUTCHMED’s SACHI Phase III Study Shows Promising Results for Lung Cancer TreatmentJune 1, 2025 | tipranks.comHUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual MeetingJune 1, 2025 | globenewswire.comHUTCHMED to Present Promising Oncology Data at 2025 ASCO MeetingMay 22, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCXI, AVIR, GWPH, ARNA, and HCM Company DescriptionsArena Pharmaceuticals NASDAQ:ARNAArena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.Atea Pharmaceuticals NASDAQ:AVIR$3.75 +0.11 (+3.02%) As of 12:47 PM EasternAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.ChemoCentryx NASDAQ:CCXIChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.GW Pharmaceuticals NASDAQ:GWPHGW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.HUTCHMED NASDAQ:HCM$15.88 +0.46 (+2.98%) As of 12:36 PM EasternHUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
